PepGen Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PEPG research report →
About the company
PepGen Inc. , a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
- CEO
- James McArthur
- IPO
- 2022
- Employees
- 56
- HQ
- Boston, MA, US
Price Chart
- Market Cap
- $121.74M
- P/E
- -0.91
- P/S
- 0.00
- P/B
- 0.91
- EV/EBITDA
- -1.27
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -59.89%
- ROIC
- -53.96%
- Revenue
- $0 · 0.00%
- Net Income
- $-89,655,000 · 0.36%
- EPS
- $-2.12 · 25.61%
- Op Income
- $-93,612,000
- FCF YoY
- 1.17%
- 52W High
- $7.80
- 52W Low
- $1.01
- 50D MA
- $1.61
- 200D MA
- $4.07
- Beta
- 1.93
- Avg Volume
- 862.57K
Get TickerSpark's AI analysis on PEPG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 18, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 34,000 |
| Jun 18, 26 | Wyman Lisa | other | 34,000 |
| Jun 18, 26 | Resnick Joshua | other | 34,000 |
| Jun 18, 26 | Mayer Howard | other | 34,000 |
| Jun 18, 26 | Finer Mitchell H. | other | 34,000 |
| Jun 18, 26 | Dable Habib J | other | 34,000 |
| Jun 18, 26 | HENSON HEIDI | other | 34,000 |
| Jun 18, 26 | KEATING LAURIE | other | 34,000 |
| May 21, 26 | Kasraian Kasra | sell | 1,233 |
| Mar 4, 26 | STRECK PAUL | sell | 1,832 |
Our PEPG coverage
Recent articles, reports, and earnings notes.
No research on PEPG yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PEPG report →Similar companies
Peers in the same neighborhood.